Navigation Links
Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia

e Cancer Center, University of Iowa, USA (Principal Investigator, USA)

SPC2996 was given by intravenous infusion on 6 repeated occasions over a two week period. Five different dosage levels were investigated. At the top dose of 4mg/kg/infusion, all 6 of the 6 patients studied showed a decrease in the severity of their leukaemia, with a rapid reduction in the numbers of circulating lymphocytes (white blood cells) being observed within 24 hours of the first administration of the drug. Five out of the 6 patients in this group showed a maximal reduction in lymphocyte count of 50% or more, indicating a clinically beneficial effect. See figure 1 attached.

A dose response to drug was also observed with patients treated with SPC2996 at 2 mg/kg/infusion having a transient reduction in lymphocytes of up to 30% and doses of 1 mg/kg/infusion having no effect.

Reductions in lymph node swelling was also observed in these patients, 2 out of 4 patients receiving drug at 4mg/kg/infusion and 1 out of 4 at 2 mg/kg/infusion showed a reduction in lymph node diameters of 50% or more. Overall, using standard clinical assessment procedures, 2 of the 6 patients treated with the top dose of drug showed a partial tumour response, one of 28-42 days and one of more than 182 days, and 3 patients had stable disease for periods of between 28 and 70 days. Mean time to disease progression was approximately twice as long (122 days) in the group receiving drug at 4mg/kg/infusion as in the groups receiving 2 or 1mg/kg/infusion (42 and 79 days).

Mechanism of Action

In cell culture and experimental models of disease, SPC2996 inhibits the production of the protein Bcl-2 and its beneficial effects in patients are thought to be due to the drug reducing Bcl-2 levels within cancerous CLL lymphocytes by binding specifically to and inactivating the messenger RNA for Bcl-2. High levels of Bcl-2 in CLL cells are associated with resistance to cancer cell death and poor disease ou
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:8/29/2014)... 29, 2014 Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... Morgan Stanley Global Healthcare Conference on Wednesday, September 10. ... Chief Executive Officer, will provide an update on the ... a.m., Pacific Daylight Time).   A webcast ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2
(Date:8/30/2014)... August 30, 2014 In today’s world, ... increasingly difficult to get. Snoring and sleep apnea (a ... breathing stops) robs people and their bed partners of ... Up to 45% of the population snores and 20 ... apnea. Of these, only 10% have been diagnosed and ...
(Date:8/30/2014)... 2014 August 28th, 2014: With ... our society and the toll that takes on the ... that continuing education for physical therapists addresses this problem. ... therapists help others, Hands-On Seminars is offering discounts on ... Three learning styles are available to fit the individual ...
(Date:8/30/2014)... FL (PRWEB) August 30, 2014 McLeod's ... full service auto repair shop with strong ties to the ... Family is happy to announce they have been chosen by ... one pick for auto repair. , Tim McLeod’s father, ... Auto Service sixty years ago. Although his son, Tim runs ...
(Date:8/30/2014)... 2014 The SI Joint Evaluation and ... six muscle energy techniques. Michael P. Reiman PT, DPT, ... examination techniques for the SI Joint. This ... live course presentation with North American Seminars. ... Applying a differential diagnosis approach to a thorough examination ...
(Date:8/30/2014)... 30, 2014 What challenges exist in ... the latest trends, concerns, and considerations? Sports Conflict ... Pendleton recently spoke with Woody Wommack, Southeast Football Recruiting ... issues in football recruiting. Notably, Wommack spoke on ... changes that he thinks are coming as a result ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3
... Response Systems,announced today two new contract awards, worth ... surge capacity for hospitals and,public health systems in ... Suffolk County, NY., The first contract, for ... the Idaho Central District Health Department. This,contract includes ...
... of connecting with doctors in real time, speeding care, study ... patients report to doctors on their symptoms and side effects ... Even the sickest cancer patients are willing and capable of ... Cancer Center in New York City. , "Cancer care has ...
... Omnicell, Inc.,(Nasdaq: OMCL ), a leading ... announced that it has entered into a definitive ... cash transaction valued at,approximately $26 million, subject to ... that brings quality healthcare to the,bedside through a ...
... rate of decline in lung function in children and adolescents ... Researchers found that patients with cystic fibrosis (CF) who took ... loss of lung function compared to those who did not ... two to seven years. , It is fairly evident ...
... Assay Developed Specifically for Resource-Limited ... Settings Joins Global Procurement Consortium, UPPSALA, Sweden, November ... today announced an agreement with the Clinton,Foundation HIV/AIDS Initiative ... immediately available to members of CHAI,s,Procurement Consortium at a ...
... Nov. 29 AstraZeneca (NYSE:,AZN) today announced that the ... an additional six-month period of,exclusivity to market ARIMIDEX(R) (anastrozole) ... to pediatric exclusivity being,granted by the FDA, the patent ... is currently approved in the US for the for ...
Cached Medicine News:Health News:BLU-MED Announces New Medical Preparedness Contracts 2Health News:Cancer Patients Gain From Reporting Symptoms Online 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 3Health News:Ibuprofen associated with slower lung function decline in children with cystic fibrosis 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 3Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 2Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 3
... Laserex Super Q is an Nd: YAG ... and reliable means for performing posterior capsulotomy, ... Q delivers benchmark performance in an elegant, ... Laserex Super Q produces a 1064 nm ...
... Ultrasonix ES500 system is an innovative, ... that provides excellent clinical performance. The ... processing of the ES500 system deliver ... and every system offers a full ...
Protects the eye during or after surgery or trauma. Smooth edges need no protective cover. Connected with elastic at nose. Adjustable hook/loop material for a comfortable fit....
Protects the eye during or after surgery or trauma...
Medicine Products: